Key benchmark indices languished in negative zone in morning trade as most Asian indices turned negative. At 10:17 IST, the barometer index, the S&P BSE Sensex, was down 77.29 points or 0.31% at 25,260.27. The Nifty 50 index was was down 21.40 points or 0.28% at 7,695.10. The Sensex and the Nifty, both, reversed direction after hitting their highest levels in almost 12 weeks. The Sensex rose 95.38 points, or 0.38% at the day's high of 25,432.94 at the onset of trading session, its highest level since 6 January 2016. The index fell 85.26 points, or 0.34% at the day's low of 25,252.30 in morning trade. The Nifty rose 32.90 points, or 0.43% at the day's high of 7,749.40 at the onset of trading session, its highest level since 6 January 2016. The index fell 25.55 points, or 0.33% at the day's low of 7,690.95 in morning trade.
The market breadth indicating the overall health of the market turned negative from positive in morning trade. On BSE, 1,027 shares fell and 849 shares rose. A total of 135 shares were unchanged. The BSE Mid-Cap index was currently down 0.38%. The decline in this index was higher than the Sensex's decline in percentage terms. The BSE Small-Cap index was currently down 0.31%. The decline in this index matched the Sensex's decline in percentage terms.
In overseas stock markets, most Asian indices reversed direction after a positive start triggered by an upward revision in US gross domestic product data. US stocks ended little-changed during the previous trading session on Thursday, 24 March 2016, after weaker-than-expected economic data. Meanwhile, St. Louis Federal Reserve President James Bullard said the relatively minor downgrades to the Fed's economic outlook suggest the next rate hike 'may not be far off provided that the economy evolves as expected.' On Friday, 25 March 2016, data showed that the US economy grew at a 1.4% seasonally adjusted annual rate in the fourth quarter, higher than a previous estimate for 1% growth.
Most pharmaceutical shares edged lower. Sun Pharmaceutical Industries (down 1.86%), Wockhardt (down 0.91%), Strides Shasun (down 0.84%), IPCA Laboratories (down 0.8%), GlaxoSmithKline Pharmaceuticals (down 0.69%), Divi's Laboratories (down 0.55%), Aurobindo Pharma (down 0.53%), Lupin (down 0.49%), Dr Reddy's Laboratories (down 0.14%) and Piramal Enterprises (down 0.09%), edged lower. Alkem Laboratories (up 0.28%), Cipla (up 0.38%) and Cadila Healthcare (up 0.39%), edged higher.
Glenmark Pharmaceuticals was up 1% at Rs 830.35. The company announced during trading hours today, 28 March 2016, that Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (USFDA) for Drospirenone and Ethinyl Estradiol Tablets USP, 3 mg/0.03 mg, the generic version of Yasmin Tablets of Bayer HealthCare Pharmaceuticals Inc. (Bayer) and for Levonorgestrel Tablet, 1.5 mg, the generic version of Plan B One-Steps Tablet of Teva Branded Pharmaceutical Products R&D, Inc., for over-the-counter (OTC) use as recommended in the submitted labeling. According to IMS Health sales data for the 12 month period ending January 2016, the Yasmie market achieved annual sales of approximately $131.7 million in the US market. According to IMS Health sales data for the 12 month period ending January 2016, the Plan B One-Steps Tablet OTC market achieved annual sales of approximately $45.2 million in the US market.
In a separate announcement, the company said that Glenmark Pharmaceuticals Inc., USA has been granted final approval by USFDA for Bendamustine Hydrochloride for Injection, 25 mg/vial and 100 mg/vial, the therapeutic equivalent to the reference listed drug product Treanda for Injection, 25 mg/vial and 100 mg/vial, of Cephalon, Inc. Under the terms of the prior settlement agreement, Glenmark will be able to launch its product on 1 November 2019 or earlier under certain circumstances. Glenmark was one of the first ANDA applicants to submit a substantially complete ANDA with a Paragraph IV certification, therefore, Glenmark may be eligible for 180 days of marketing exclusivity for Bendamustine Hydrochloride for Injection, 25 mg/vial and 100 mg/vial. According to IMS Health sales data for the 12 month period ending January 2016, the Treanda for Injection, 25 mg/vial and 100 mg/vial Market achieved annual sales of approximately $92.6 million in the US market.
Metal shares edged lower. Vedanta (down 3.82%), Hindalco Industries (down 2.47%), Bhushan Steel (down 2.26%), Steel Authority of India (down 2.1%), NMDC (down 1.72%), National Aluminium Company (down 1.68%), Tata Steel (down 1.03%), JSW Steel (down 0.91%), Jindal Steel & Power (down 0.88%), Hindustan Copper (down 0.86%) and Hindustan Zinc (down 0.35%), edged lower.
More From This Section
Copper edged higher in the global commodities market. High Grade Copper for May 2016 delivery was currently up 0.56% at $2.2415 per pound on the COMEX.
Bharat Heavy Electricals (Bhel) rose 0.09% after the company announced that it has commissioned 600 megawatts coal-based thermal power plant in Telangana. Bhel said that the power plant was commissioned at the upcoming 1200 megawatts (MW) Singareni Thermal Power Project located in Adilabad district in Telangana. The second unit of Singareni Thermal Power Project is also in an advanced stage of construction and is expected to be commissioned shortly. The project is being developed by Singareni Collieries Company (SCCL), a coal mining company. The announcement was made on Friday, 25 March 2016. The stock market was closed on that day for a holiday.
Powered by Capital Market - Live News